Robert Chess Biography and Net Worth

Robert B. Chess is the Chairman of Nektar’s Board of Directors and has served as a Director since May 1992. Mr. Chess currently is the Chairman and Co-Founder of Biota Technology, a private company developing applications of DNA-sequencing for the energy industry, and is Lead Director at Twist Biosciences, which manufactures synthetic DNA using a silicon-based synthesis platform. From March 2006 until January 2007, Mr. Chess served as our Acting President and Chief Executive Officer, and from April 1999 to January 2007, served as Executive Chairman. He also served as our Co-Chief Executive Officer from August 1998 to April 2000, as President from December 1991 to August 1998, and as Chief Executive Officer from May 1992 to August 1998. Mr. Chess was previously CEO and Chairman of OPX Biotechnologies, a renewable chemicals company, which was sold to Cargill, and the Co-Founder and President of Penederm, Inc., a publicly-traded pharmaceutical dermatology company that was acquired by Mylan Laboratories. He has held management positions at Intel Corporation and Metaphor Computer Systems (now part of IBM), and was a member of President George H.W. Bush's White House staff as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy.

From 1997 to 2009, Mr. Chess served on the Board of Directors of the Biotechnology Industry Organization (BIO) where he was Chairman of BIO's Emerging Companies Section and Co-Chairman of BIO's Intellectual Property Committee. Mr. Chess was the initial Chairman of Bio Ventures for Global Health and continues to serve on its board. He also serves on the Board of Trustees of the California Institute of Technology, where he chairs the Technology Transfer Committee and has taught entrepreneurship as a visiting professor. He is currently a member of the faculty of the Stanford Graduate School of Business, where he teaches courses in the MBA program on entrepreneurship and on the healthcare industry. Mr. Chess received his B.S. degree in Engineering with honors from the California Institute of Technology and his MBA from Harvard Business School.

What is Robert Chess' net worth?

The estimated net worth of Robert Chess is at least $21,641.00 as of November 11th, 2024. Mr. Chess owns 21,641 shares of Nektar Therapeutics stock worth more than $21,641 as of November 20th. This net worth estimate does not reflect any other assets that Mr. Chess may own. Learn More about Robert Chess' net worth.

How do I contact Robert Chess?

The corporate mailing address for Mr. Chess and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected]. Learn More on Robert Chess' contact information.

Has Robert Chess been buying or selling shares of Nektar Therapeutics?

Robert Chess has not been actively trading shares of Nektar Therapeutics during the past quarter. Most recently, Robert Chess sold 19,500 shares of the business's stock in a transaction on Friday, June 14th. The shares were sold at an average price of $1.20, for a transaction totalling $23,400.00. Following the completion of the sale, the director now directly owns 255,273 shares of the company's stock, valued at $306,327.60. Learn More on Robert Chess' trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 150,299 shares worth more than $212,676.87. The most recent insider tranaction occured on August, 19th when insider Jonathan Zalevsky sold 6,866 shares worth more than $8,788.48. Insiders at Nektar Therapeutics own 3.7% of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 8/19/2024.